This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 118/14/1425    most recent CIRCULATIONAHA.108.777102v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schächinger, V. Articles by Zeiher, A. M. Search for Related Content PubMed PubMed Citation Articles by Schächinger, V. Articles by Zeiher, A. M. Pubmed/NCBI databases Medline Plus Health Information Heart Attack Stem Cells Related Collections Other heart failure Catheter-based coronary and valvular interventions: other Coronary imaging: angiography/ultrasound/Doppler/CC Nuclear cardiology and PET Acute myocardial infarction Chronic ischemic heart disease Coronary circulation Related Article

(Circulation. 2008;118:1425-1432.)
© 2008 American Heart Association, Inc.

Heart Failure

Pilot Trial on Determinants of Progenitor Cell Recruitment to the Infarcted Human Myocardium

Volker Schächinger, MD^*; Alexandra Aicher, MD^*; Natascha Döbert, MD; Rainer Röver, BSc; Jürgen Diener, MD; Stephan Fichtlscherer, MD; Birgit Assmus, MD; Florian H. Seeger, MD; Christian Menzel, MD; Winfried Brenner, MD; Stefanie Dimmeler, PhD; Andreas M. Zeiher, MD

From the Department of Medicine III, Division of Cardiology (V.S., A.A., R.R., S.F., B.A., F.H.S., S.D., A.M.Z.), and Department of Nuclear Medicine (N.D., J.D., C.M.), J.W. Goethe University Frankfurt, Frankfurt am Main, and Department of Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Hamburg (W.B.), Germany.

Correspondence to Andreas M. Zeiher, J.W. Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany. E-mail Zeiher{at}em.uni-frankfurt.de

Received October 4, 2007; accepted June 30, 2008.

Background— Clinical trials indicate a beneficial effect of intracoronary infusion of progenitor cells on myocardial function in patients with ischemic heart disease. The extent and potential determinants of proangiogenic progenitor cell homing into the damaged myocardium after intracoronary infusion and the underlying mechanisms are still unknown.

Method and Results— Circulating proangiogenic progenitor cells isolated from peripheral blood and cultivated for 3 days were labeled with radioactive indium oxine (¹¹¹In-oxine). Radiolabeled proangiogenic progenitor cells (7.6±3.0 MBq, mean±SD) were administered to patients with previous myocardial infarction and a revascularized infarct vessel at various stages after infarction (5 days to 17 years). Viability of the infarcted myocardium was determined by ¹⁸F-fluorodeoxyglucose–positron emission tomography and microcirculatory function by intracoronary Doppler measurements. One hour after application of progenitor cells, a mean of 6.9±4.7% (range, 1% to 19%; n=17) of total radioactivity was detected in the heart, which declined to 2±1% after 3 to 4 days. Average activity within the first 24 hours was highest among patients with acute myocardial infarction (14 days; 6.3±2.9%; n=8) and progressively decreased in patients treated in an intermediate phase (>14 days to 1 year; 4.5±3.2%; n=4) or a chronic stage (infarct age >1 year; 2.5±1.6%; n=5). Low viability of the infarcted myocardium and reduced coronary flow reserve were significant (P<0.05) predictors of proangiogenic progenitor cell homing.

Conclusions— In patients after myocardial infarction undergoing intracoronary infusion of ¹¹¹In-oxine–labeled proangiogenic progenitor cells, a substantial amount of radioactivity is detected for several days in the heart, indicating homing of progenitor cells to the myocardium. The amount of proangiogenic progenitor cells retained in the heart decreased progressively with time after the acute myocardial infarction. Proangiogenic progenitor cells preferentially home to extensive acute myocardial infarcts characterized by low viability and reduced coronary flow reserve.

---

 

CLINICAL PERSPECTIVE

Related Article:

Clinical Summaries
Circulation 2008 118: 1403-1404. [Extract] [Full Text]

This article has been cited by other articles:

				B. J. Gersh, R. D. Simari, A. Behfar, C. M. Terzic, and A. Terzic Cardiac Cell Repair Therapy: A Clinical Perspective Mayo Clin. Proc., October 1, 2009; 84(10): 876 - 892. [Abstract] [Full Text] [PDF]

				U. Fischer-Rasokat, B. Assmus, F. H. Seeger, J. Honold, D. Leistner, S. Fichtlscherer, V. Schachinger, T. Tonn, H. Martin, S. Dimmeler, et al. A Pilot Trial to Assess Potential Effects of Selective Intracoronary Bone Marrow-Derived Progenitor Cell Infusion in Patients With Nonischemic Dilated Cardiomyopathy: Final 1-Year Results of the Transplantation of Progenitor Cells and Functional Regeneration Enhancement Pilot Trial in Patients With Nonischemic Dilated Cardiomyopathy Circ Heart Fail, September 1, 2009; 2(5): 417 - 423. [Abstract] [Full Text] [PDF]

				S. J. Brunskill, C. J. Hyde, C. J. Doree, S. M. Watt, and E. Martin-Rendon Route of delivery and baseline left ventricular ejection fraction, key factors of bone-marrow-derived cell therapy for ischaemic heart disease Eur J Heart Fail, September 1, 2009; 11(9): 887 - 896. [Abstract] [Full Text] [PDF]

				F. M. Bengel Clinical Cardiovascular Molecular Imaging J. Nucl. Med., June 1, 2009; 50(6): 837 - 840. [Abstract] [Full Text] [PDF]